Platelet Sub-study of the Neomindset Trial - Trial NCT05767723
Access comprehensive clinical trial information for NCT05767723 through Pure Global AI's free database. This Phase 4 trial is sponsored by Hospital Israelita Albert Einstein and is currently Recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Interventional
drug
Sponsor & Location
Hospital Israelita Albert Einstein
Timeline & Enrollment
Phase 4
Feb 06, 2023
Mar 06, 2024
Primary Outcome
Platelet function using PFA-100
Summary
The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for
 ischemic events and the superiority hypothesis for bleeding events resulting from platelet
 P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual
 antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary
 intervention.
 
 The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This
 sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet
 function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or
 dual antiplatelet therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05767723
Non-Device Trial